| pubmed-article:7436563 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C0021562 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C0018099 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C0040209 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:7436563 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:7436563 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7436563 | pubmed:dateCreated | 1981-1-26 | lld:pubmed |
| pubmed-article:7436563 | pubmed:abstractText | Under inpatient controlled conditions 4 patients with gout and hypertension were treated with varying doses of tienilic acid, a new uricosuric diuretic. Plasma urate levels were reduced by an average of 50% in association with significantly increased urinary urate excretion. A twice-daily regimen was considerably more effective than a single morning dosage in reduction of plasma urate, though both regimens were equally effective in antihypertensive potency. The single daily regimen produced greater diurnal fluctuations in plasma urate and was more frequently associated with the development of acute gout attacks. | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7436563 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7436563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7436563 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7436563 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7436563 | pubmed:issn | 0003-4967 | lld:pubmed |
| pubmed-article:7436563 | pubmed:author | pubmed-author:ScottJ TJT | lld:pubmed |
| pubmed-article:7436563 | pubmed:author | pubmed-author:ReardonJ AJA | lld:pubmed |
| pubmed-article:7436563 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7436563 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:7436563 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7436563 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7436563 | pubmed:pagination | 367-72 | lld:pubmed |
| pubmed-article:7436563 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:meshHeading | pubmed-meshheading:7436563-... | lld:pubmed |
| pubmed-article:7436563 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7436563 | pubmed:articleTitle | Controlled inpatient study of tienilic acid in treatment of gout and hypertension. | lld:pubmed |
| pubmed-article:7436563 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7436563 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7436563 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7436563 | lld:pubmed |
